drugset / Trial / NCT00641160

Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies

NCT00641160

Phase 1 Unknown 12 enrolled Metronome Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of oral administration of vinorelbine once daily for at least 7 days. The study will be conducted in subjects with a non-hematologic malignancy for which there are no currently accepted therapies.

Timeline

Start
2008-03
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinorelbine Small molecule Oral

Indications

No indication recorded.